Thermo Fisher Scientific (NYSE:TMO), the world leader in serving science, reported financial results for the fourth quarter and full year ended December 31, 2025.
Fourth-quarter revenue grew 7% to $12.21 billion.
GAAP diluted earnings per share increased 9% to $5.21, while adjusted EPS rose 8% to $6.57.
For the full year, revenue increased 4% to $44.56 billion.
While GAAP diluted EPS grew 7% to $17.74, adjusted EPS rose 5% to $22.87.
Looking ahead to 2026, Thermo Fisher issued a bullish outlook, targeting organic revenue growth between 3% and 6%.
The company is also doubling down on its "Path to AI," recently announcing a strategic collaboration with NVIDIA to integrate generative AI into its laboratory instrumentation.
With $3.6 billion in cash and a newly authorized $5 billion share repurchase program, the company is positioning itself to outpace market growth while continuing its history of aggressive capital deployment.